Filana Therapeutics, Inc
NASDAQ:FLNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Filana Therapeutics, Inc
NASDAQ:FLNA
|
US |
|
G
|
Grandshores Technology Group Ltd
HKEX:1647
|
SG |
|
C
|
Craftport Cannabis Corp
CNSX:CFT
|
CA |
|
Rapid Nutrition PLC
PAR:ALRPD
|
UK |
|
Growthpoint Properties Australia Ltd
OTC:GRWPF
|
AU |
|
Kadestone Capital Corp
XTSX:KDSX
|
CA |
|
B
|
Brg SA
WSE:BER
|
PL |
|
Denali Capital Acquisition Corp
NASDAQ:DECA
|
US |
|
Generations Bancorp NY Inc
NASDAQ:GBNY
|
US |
|
C
|
Carraro India Ltd
NSE:CARRARO
|
IN |
|
M
|
McCormick & Company Inc
SWB:MCX
|
US |
|
Ecora Resources PLC
LSE:ECOR
|
UK |
|
Man Sang International Ltd
HKEX:938
|
HK |
Filana Therapeutics, Inc
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
